Ebola antibody cocktail made available in emergency outbreak
NCT ID NCT03576690
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This program provides emergency access to REGN-EB3, a combination of three antibodies, for people with confirmed Ebola virus disease. It is available to both adults and children in Ebola-affected regions, including pregnant women. The goal is to offer a potential treatment option during outbreaks when no other approved therapies are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN-EB3 (a combination of three antibodies: atoltivimab, maftivimab, and odesivimab)
What this could lead to
If effective, this treatment could help control Ebola virus disease and improve survival rates during outbreaks.
What could go wrong
This is an expanded access program, not a controlled trial, so results may be less reliable. The treatment may not work for all patients and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••